-transparent.png){kind=logo}
The clinical experience of 1,723 patients treated with imipenem/cilastatin in worldwide clinical trials is reviewed. Dosages of imipenem administered parenterally with cilastatin varied with the severity of the infection and included 250 mg four times a day; 500 mg three or four times a day, and 1 g three of four times a day. Infections of all body systems except the central nervous system due to gram-positive or gram-negative aerobes and anaerobes as well as those due to mixed organisms were treated. Clinical efficacy was demonstrated in 92% of infections. The adverse clinical and laboratory experiences associated with imipenem/cilastatin were similar to those of other beta-lactam agents and included disturbances of gastrointestinal and central nervous system function, allergic reactions, and transient elevations of liver enzyme levels.
C Wang, and
G B Calandra, and
M A Aziz, and
K R Brown
January 1991,
Chemotherapy,
C Wang, and
G B Calandra, and
M A Aziz, and
K R Brown
January 1985,
Reviews of infectious diseases,
C Wang, and
G B Calandra, and
M A Aziz, and
K R Brown
January 1985,
Reviews of infectious diseases,
C Wang, and
G B Calandra, and
M A Aziz, and
K R Brown
January 1985,
Reviews of infectious diseases,
C Wang, and
G B Calandra, and
M A Aziz, and
K R Brown
November 1985,
Drug intelligence & clinical pharmacy,
C Wang, and
G B Calandra, and
M A Aziz, and
K R Brown
February 1991,
La Clinica terapeutica,
C Wang, and
G B Calandra, and
M A Aziz, and
K R Brown
June 2021,
Infection & chemotherapy,
C Wang, and
G B Calandra, and
M A Aziz, and
K R Brown
January 1985,
Reviews of infectious diseases,
C Wang, and
G B Calandra, and
M A Aziz, and
K R Brown
December 1986,
The Journal of antimicrobial chemotherapy,
C Wang, and
G B Calandra, and
M A Aziz, and
K R Brown
November 1988,
The Japanese journal of antibiotics,
